Melanoma Treatment Options One Step Closer Oct 21, 2009
20, 2009) A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease. U of A chemistry professor Dennis Hall said after three years of work, his research team has successfully produced the substance called Palmerolide A.. (Science Daily)
Survivor stresses early detection in success of breast cancer recovery Oct 19, 2009
Once diagnosed, she and her oncologist, Dr. Timothy Pluard, decided on a treatment strategy using Taxotere, Carboplatin and Herceptin. I chose a course of six months of chemotherapy, one year of Herceptin treatments and radiation therapy, Strawn said. (Mattoon Journal-Gazette, IL)
DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells Oct 11, 2009
Therefore the measurement of the DNA damage induced by cis- and carboplatin should reflect the sensitivity of cancer cells toward the platinum chemotherapeutics ... DNA damage induced by cis- and carboplatin in primary cells of ovarian carcinomas was determined by the alkaline comet assay ... DNA damage after a one day treatment with cis- or carboplatin correlated well with the cytotoxic effects after a 7 day treatment (r = 0,942 for cisplatin r = 0. (BioMed Central)
New Mesothelioma Treatment Options Oct 2, 2009
Doctors are exploring the effectiveness of carboplatin, Avastin, and Altima in patients newly diagnosed with malignant pleural mesothelioma. The standard treatment approach for newly diagnosed mesothelioma patients is a combination of the chemotherapy drugs cisplatin or carboplatin and Altima. (Suite101.com)
New Chemo Regimen May Benefit Ovarian Cancer Patients Sep 22, 2009
Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer ... Both groups received carboplatin on day one of a 21-day cycle. (MEDLINEplus)
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Sep 3, 2009
NEJM -- Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma ... Gefitinib or Carboplatin Paclitaxel in Pulmonary Adenocarcinoma ... Methods In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per... (New England Journal of Medicine)
Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy Aug 2, 2009
To find out if patients whose disease is no longer controlled by cetuximab can respond to erlotinib, Borghaei and colleagues examined the treatment and clinical outcomes for a subgroup of patients who had participated in a Fox Chase clinical trial that tested a combination of carboplatin, paclitaxel and cetuximab as first-line treatment for advanced non-small cell lung cancer. Out of 53 patients who had participated in that trial, the investigators identified 15 individuals who had received... (EurekAlert!)
OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position Jul 30, 2009
The combination regimen of ZYBRESTAT and carboplatin plus paclitaxel chemotherapy was well-tolerated with approximately half of the patients completing all 6 cycles of therapy. In April, the Company reported data at the American Association of Cancer Research (AACR) annual meeting showing that OXi4503 has pronounced antitumor activity when administered as a single agent or in combination with chemotherapy in an acute myelogenous leukemia (AML) xenograft model. (Primezone Releases)
BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer Jul 17, 2009
The Phase 3 trial is a multi-center, randomized trial designed to evaluate the safety and efficacy of BSI-201 when combined with gemcitabine and carboplatin (GC) in women with mTNBC. A total of 420 mTNBC patients, who have received 0-2 prior therapies in the metastatic setting, will be randomized to receive GC with or without BSI-201. The co-primary objectives of this study are to assess improvement in progression-free survival and overall survival. (Primezone Releases)
Wilmington audiologist warns against hearing loss for cancer patients Jun 30, 2009
Specifically, three chemotherapy drugs cisplatin, carboplatin, and mechlorethamine have been associated with hearing problems. In addition, other common drugs prescribed to cancer patients can impact inner ear health. (Wilmington Advocate, MA)
Drug Combination Improves Outcome For Advanced Non-small Cell Lung Cancer Jun 2, 2009
14, 2008) The four-drug combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab and cetuximab, is safe and may improve survival for patients with advanced lung cancer, according to a. . (Science Daily)
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients Jun 1, 2009
GEMZAR is indicated in combination with carboplatin (another type of chemotherapy) for the patient with ovarian cancer that has returned at least 6 months after the patient had finished platinum-based therapy. GEMZAR is indicated as a single agent (given alone) as the first-line treatment for patients with locally advanced (Stage II or Stage III when surgery is not an option) or metastatic (Stage IV) adenocarcinoma of the pancreas. (PR Newswire)
Sanofi's Viebacher Lands Cancer Drug by Paying $500 Million for 18 People Jun 1, 2009
In Sanofis study, half of patients were given BSI-201 and a combination of chemotherapies, carboplatin and Eli Lilly & Co.s Gemzar, and half were given chemotherapy and a placebo. About 60 percent of patients who took BSI-201 saw their tumors shrink and cancer slow, almost three times as many as those who took only chemotherapy. (Bloomberg -- US)
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival Jun 1, 2009
May 31, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE: - ) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage. (Primezone Releases)
Get a free hearing screening May 30 May 29, 2009
Frank Pantina, above, is a registered pharmacist and sole owner of Cross Bay Chemist, located at 158-14 Cross Bay Boulevard in Howard Beach (Queens Chronicle, NY)
Frank Pantina, above, is a registered pharmacist and sole owner of Cross Bay Chemist, located at 158-14 Cross Bay Boulevard in Howard Beach. (photo by Frank Pantina)"> May 29, 2009
Queens Chronicle - Get a free hearing screening May 30. Get a free hearing screening May 30 05/28/2009. (Queens Chronicle, NY)
Cancer Researchers In Bakersfield Seek Volunteers May 23, 2009
Study volunteers will be randomized to either six cycles of docetaxel and carboplatin or three cycles of docetaxel, followed by three cycles of 5FU, epirubicin and cyclophosphamide, a regimen called FEC. One group will also get Herceptin, while the other will get Herceptin and Avastin. Herceptin is already the standard of care across all stages of HER2-positive breast cancer and has a proven survival benefit. (KERO 23, CA)
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology May 21, 2009
Abstract #5502 Session: New Advances in Gynecologic Cancers Title: Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results Authors: M.Zweifel, G. Jayson, N. Reed, R. Osborne, B. Hassan, G. Shreeves, L. Poupard, P. Walicke, J. Balkissoon, D. Chaplin, G. Rustin Time: Monday, June 1, 2009, 9:45-11:15 am Room: Level 3, Chapin Theater, W 320, Orange County Convention Center. OXi4503 Abstract Published Online in... (Primezone Releases)
Telik Reports Preclinical Results at AACR Annual Meeting Apr 29, 2009
TLK58747 inhibited the growth of nine established cell lines of various tumor types and retained its effectiveness against cancer cell lines resistant to standard cancer chemotherapeutics including adriamycin, paclitaxel, and carboplatin. Treatment of human cancer cells with TLK58747 led to the activation of the DNA damage-response pathway, and produced G2/M cell cycle arrest in human solid tumor cell lines. (PR Newswire)
Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers Apr 20, 2009
"By examining gene expression data, we determined that the combination of the leukemia drug dasatinib (Sprycel) made carboplatin and paclitaxel more effective in cell lines with higher levels of SRC expression and SRC pathway deregulation." ... All were treated in lab dishes with various combinations of the chemotherapeutic agents dasatinib, carboplatin and paclitaxel ... Currently a phase I trial of a combination of dasatinib, paclitaxel and carboplatin is available for women with advanced or... (EurekAlert!)
OXiGENE Announces Publication of Phase 2 Study Results With Fosbretabulin (ZYBRESTAT(tm)) Monotherapy in Anaplastic Thyroid Cancer (ATC) Mar 17, 2009
The pivotal registration Phase 2/3 FACT (fosbretabulin in anaplastic cancer of the thyroid) trial is a 180-patient, multicenter, open-label, randomized study in patients with anaplastic thyroid cancer to evaluate the safety and efficacy of fosbretabulin (dosed at 60 mg/m2) in combination with paclitaxel and carboplatin in comparison with paclitaxel and carboplatin alone. The FACT trial is actively recruiting and enrolling patients with regionally-advanced or metastatic anaplastic thyroid cancer... (Primezone Releases)
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 Mar 5, 2009
Selected Highlights: Clinical Trial Results ---------------------- - Announced positive interim results from our Phase I/II UK combination REOLYSIN and carboplatin/paclitaxel trial ... Clinical Trial Progress ----------------------- - Selection of first pivotal program using REOLYSIN in combination with paclitaxel and carboplatin for patients with platinum-failed head & neck cancers; - Start of patient enrolment in five new trials: - NCI-sponsored Phase I/II systemic and peritoneal... (PR Newswire)
Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial Feb 12, 2009
MONET1 is a Phase 3 study evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced NSCLC. Motesanib is part of a co-development program between Amgen, Millennium and Takeda ... Patients were randomized 1:1 to receive paclitaxel and carboplatin administered every three weeks with or without 125 mg motesanib taken daily. (PR Newswire)
Lung Cancer May Be Deadlier for Men Feb 7, 2009
The study found that the use of two targeted therapies (bevacizumab and cetuximab) with chemotherapy (carboplatin and paclitaxel) as first-line treatment improved the survival of 104 patients who were evaluated between August 2006 and September 2007. There were no safety concerns. (MEDLINEplus)
